葵花药业：关于2022年员工持股计划股份出售完毕暨终止的公告

Core Points - The company, Kewang Pharmaceutical, announced the completion of its employee stock ownership plan, with a total of 2,950,060 shares sold through the secondary market, representing 0.51% of the company's total share capital [2] Group 1 - The employee stock ownership plan was fully executed and terminated ahead of schedule, with subsequent asset liquidation and distribution processes to follow [2] - The company adhered to market trading rules and regulations set by the China Securities Regulatory Commission and the Shenzhen Stock Exchange during the implementation of the employee stock ownership plan [2] - No insider information was utilized for trading during the implementation period of the employee stock ownership plan [2]